Skip to content

Released May 5, 2026, after the close

10-Q filed May 6, 2026, 36 days after period end · 0001193125-26-208967

Q1 2026 · 10-Q
Revenue$21.15M+4.6% vs Q1 2025−11.1% vs Q4 2025
Net Income$127.07MN/M vs Q1 2025+559.0% vs Q4 2025
EPS Diluted$0.33N/M vs Q1 2025no prior Q4 2025 on file
Gross Profit$11,308,000+2.3%
Operating Income-$12,496,000N/M
Operating Cash Flow-$46,597,000N/M
Free Cash Flowderived-$47,167,000N/M
Margins · derived
Gross margin53.5%−1.2 pt vs Q1 2025
Operating margin-59.1%+74.3 pt vs Q1 2025
Net margin600.9%+729.6 pt vs Q1 2025

What the release said

The release

Same quarter

MetricQ1 2026Q1 2025Q1 2024Q1 2023
Revenue$21.15M$20.22M$45.54M$25.12M
Net Income$127.07M-$26.03M-$32.16M-$16.84M
EPS Diluted$0.33-$0.07-$0.27-$0.21

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR